7Lun·

$HIMS (-0,44 %)

The FDA will discuss whether or not the GLP-1 "Tirzepatide" is still in short supply towards the end of the trading day tomorrow, after the Outsourcing Facilities Association took legal action against the FDA's decision to remove the weight loss drug from the shortage list. If the FDA were to declare the shortage over, many fear that Semaglutide will soon be removed from the list as well.

8
4 Comentarios

Imagen de perfil
I wouldn't be surprised if this news also dragged the share down
3
Imagen de perfil
@Semos25 it would, because that would mean the imminent shortage end for Semaglutide. It's crazy what happens here every day. I've been investing in HIMS for two years now, but I've never experienced a time like now, where it goes up or down 10 percent every day 😂😂
2
Imagen de perfil
@Leipziger_Jung I think so too. You really need good nerves. Let's see how long that lasts
2
Imagen de perfil
Update: The FDA has decided to postpone its decision until December 19
Únase a la conversación